News
ACell Announces CE Mark Approval
Columbia, MD, December 22, 2020 ‐‐ ACell, Inc., a leading regenerative medicine company, announced today that it has received CE mark approval for its MicroMatrix®, Cytal® Wound Matrix, and Cytal® Burn Matrix devices. This regulatory approval allows ACell to distribute these products throughout the 27 countries of the European Union.
Integra LifeSciences Announces Definitive Agreement To Acquire ACell, Inc.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) a leading global medical technology company, today announced it has entered into a definitive agreement to acquire ACell, Inc. (“ACell”) for an upfront cash payment of $300 million at closing,...
ACell Launches Gentrix Hiatal at Society of Laparoendoscopic Surgeons Meeting
Gentrix Hiatal to receive Innovation of the Year Award at SLS Minimally Invasive Surgery Week for providing a new solution to hiatal hernia repair and reinforcement.
ACell and Southmedic Announce Canadian Launch of Gentrix Surgical Matrix Family of Products
ACell and Southmedic are excited to showcase the newly launched line of reinforcement devices for hernia and abdominal wall repair at the 2019 Canadian Surgery Forum.
ACell Receives Supplier Legacy Award from Premiere Inc.
ACell was recognized for its long-standing support of Premier members through exceptional local customer service, engagement, and value creation.
ACell Enters Exclusive Chinese Product Supply and Distribution Agreement for Cytal and MicroMatrix Wound Management Products
Columbia, MD— (April 8, 2019) ACell, Inc. today announced that it has entered into an exclusive longterm product supply and distribution agreement with First Horizon, LLC and Weihai Jierui Medical...
ACell Announces Additional Clearances for Gentrix Surgical Matrix Family of Products
Columbia, MD — (April 3, 2019) – ACell, Inc. today announced that it has received a new 510(k) clearance from the US Food and Drug Administration (FDA) covering several devices...
ACell Announces Research Published in Science Translational Medicine
Pre-Clinical Model Showed Delayed Tumor Growth in the Presence of MatriStem UBM™ Particulate Columbia, MD — (March 25, 2019) – ACell, Inc. today announced publication of the article entitled “A...
ACell Enters Exclusive South Korean Distribution Agreement for Wound Management Product Line
Columbia, MD— (March 18, 2019) ACell, Inc. today announced that it has entered into an exclusive distribution agreement with MyungMoon Bio Co. Ltd. MyungMoon is a leading manufacturer and distributor...
ACell Announces Participation in Arab Health 2019
Columbia, MD — (January 22, 2019) – ACell, Inc. today announced their participation in Arab Health 2019, being held January 28-31 in in Dubai. ACell will be part of the...
